Show simple item record

dc.contributor.authorDavidson, Karina W.
dc.contributor.authorPbert, Lori
dc.contributor.authorUS Preventive Services Task Force
dc.date2022-08-11T08:10:19.000
dc.date.accessioned2022-08-23T17:04:08Z
dc.date.available2022-08-23T17:04:08Z
dc.date.issued2022-01-25
dc.date.submitted2022-02-23
dc.identifier.citation<p>US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Epling JW Jr, Kubik M, Li L, Ogedegbe G, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB. Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement. JAMA. 2022 Jan 25;327(4):360-367. doi: 10.1001/jama.2021.23732. PMID: 35076659. <a href="https://doi.org/10.1001/jama.2021.23732">Link to article on publisher's site</a></p>
dc.identifier.issn0098-7484 (Linking)
dc.identifier.doi10.1001/jama.2021.23732
dc.identifier.pmid35076659
dc.identifier.urihttp://hdl.handle.net/20.500.14038/44574
dc.description<p>Full author list omitted for brevity. For the full list of authors, see article.</p>
dc.description.abstractImportance: Atrial fibrillation (AF) is the most common cardiac arrhythmia. The prevalence of AF increases with age, from less than 0.2% in adults younger than 55 years to about 10% in those 85 years or older, with a higher prevalence in men than in women. It is uncertain whether the prevalence of AF differs by race and ethnicity. Atrial fibrillation is a major risk factor for ischemic stroke and is associated with a substantial increase in the risk of stroke. Approximately 20% of patients who have a stroke associated with AF are first diagnosed with AF at the time of the stroke or shortly thereafter. Objective: To update its 2018 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the benefits and harms of screening for AF in older adults, the accuracy of screening tests, the effectiveness of screening tests to detect previously undiagnosed AF compared with usual care, and the benefits and harms of anticoagulant therapy for the treatment of screen-detected AF in older adults. Population: Adults 50 years or older without a diagnosis or symptoms of AF and without a history of transient ischemic attack or stroke. Evidence Assessment: The USPSTF concludes that evidence is lacking, and the balance of benefits and harms of screening for AF in asymptomatic adults cannot be determined. Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for AF. (I statement).
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=35076659&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.1001/jama.2021.23732
dc.subjectCardiovascular Diseases
dc.subjectCommunity Health and Preventive Medicine
dc.subjectNervous System Diseases
dc.subjectPreventive Medicine
dc.titleScreening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement
dc.typeJournal Article
dc.source.journaltitleJAMA
dc.source.volume327
dc.source.issue4
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/prc_pubs/167
dc.identifier.contextkey28259813
html.description.abstract<p>Importance: Atrial fibrillation (AF) is the most common cardiac arrhythmia. The prevalence of AF increases with age, from less than 0.2% in adults younger than 55 years to about 10% in those 85 years or older, with a higher prevalence in men than in women. It is uncertain whether the prevalence of AF differs by race and ethnicity. Atrial fibrillation is a major risk factor for ischemic stroke and is associated with a substantial increase in the risk of stroke. Approximately 20% of patients who have a stroke associated with AF are first diagnosed with AF at the time of the stroke or shortly thereafter.</p> <p>Objective: To update its 2018 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the benefits and harms of screening for AF in older adults, the accuracy of screening tests, the effectiveness of screening tests to detect previously undiagnosed AF compared with usual care, and the benefits and harms of anticoagulant therapy for the treatment of screen-detected AF in older adults.</p> <p>Population: Adults 50 years or older without a diagnosis or symptoms of AF and without a history of transient ischemic attack or stroke.</p> <p>Evidence Assessment: The USPSTF concludes that evidence is lacking, and the balance of benefits and harms of screening for AF in asymptomatic adults cannot be determined.</p> <p>Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for AF. (I statement).</p>
dc.identifier.submissionpathprc_pubs/167
dc.contributor.departmentPrevention Research Center
dc.contributor.departmentDepartment of Population and Quantitative Health Sciences, Division of Preventive and Behavioral Medicine
dc.source.pages360-367


This item appears in the following Collection(s)

Show simple item record